These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28539448)

  • 1. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.
    Julg B; Pegu A; Abbink P; Liu J; Brinkman A; Molloy K; Mojta S; Chandrashekar A; Callow K; Wang K; Chen X; Schmidt SD; Huang J; Koup RA; Seaman MS; Keele BF; Mascola JR; Connors M; Barouch DH
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28539448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
    Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
    J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.
    Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
    Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early antibody therapy can induce long-lasting immunity to SHIV.
    Nishimura Y; Gautam R; Chun TW; Sadjadpour R; Foulds KE; Shingai M; Klein F; Gazumyan A; Golijanin J; Donaldson M; Donau OK; Plishka RJ; Buckler-White A; Seaman MS; Lifson JD; Koup RA; Fauci AS; Nussenzweig MC; Martin MA
    Nature; 2017 Mar; 543(7646):559-563. PubMed ID: 28289286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding.
    Rosenberg YJ; Jiang X; Cheever T; Coulter FJ; Pandey S; Sack M; Mao L; Urban L; Lees J; Fischer M; Smedley J; Sidener H; Stanton J; Haigwood NL
    J Virol; 2021 Aug; 95(18):e0026821. PubMed ID: 34190597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.
    Shingai M; Nishimura Y; Klein F; Mouquet H; Donau OK; Plishka R; Buckler-White A; Seaman M; Piatak M; Lifson JD; Dimitrov DS; Nussenzweig MC; Martin MA
    Nature; 2013 Nov; 503(7475):277-80. PubMed ID: 24172896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.
    Barouch DH; Whitney JB; Moldt B; Klein F; Oliveira TY; Liu J; Stephenson KE; Chang HW; Shekhar K; Gupta S; Nkolola JP; Seaman MS; Smith KM; Borducchi EN; Cabral C; Smith JY; Blackmore S; Sanisetty S; Perry JR; Beck M; Lewis MG; Rinaldi W; Chakraborty AK; Poignard P; Nussenzweig MC; Burton DR
    Nature; 2013 Nov; 503(7475):224-8. PubMed ID: 24172905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption.
    Hsu DC; Schuetz A; Imerbsin R; Silsorn D; Pegu A; Inthawong D; Sopanaporn J; Visudhiphan P; Chuenarom W; Keawboon B; Shi W; Robb ML; Mascola JR; Geleziunas R; Koup RA; Barouch DH; Michael NL; Vasan S
    PLoS Pathog; 2021 Feb; 17(2):e1009339. PubMed ID: 33600506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.
    Borducchi EN; Liu J; Nkolola JP; Cadena AM; Yu WH; Fischinger S; Broge T; Abbink P; Mercado NB; Chandrashekar A; Jetton D; Peter L; McMahan K; Moseley ET; Bekerman E; Hesselgesser J; Li W; Lewis MG; Alter G; Geleziunas R; Barouch DH
    Nature; 2018 Nov; 563(7731):360-364. PubMed ID: 30283138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.
    Julg B; Liu PT; Wagh K; Fischer WM; Abbink P; Mercado NB; Whitney JB; Nkolola JP; McMahan K; Tartaglia LJ; Borducchi EN; Khatiwada S; Kamath M; LeSuer JA; Seaman MS; Schmidt SD; Mascola JR; Burton DR; Korber BT; Barouch DH
    Sci Transl Med; 2017 Sep; 9(408):. PubMed ID: 28931655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.
    Liu J; Ghneim K; Sok D; Bosche WJ; Li Y; Chipriano E; Berkemeier B; Oswald K; Borducchi E; Cabral C; Peter L; Brinkman A; Shetty M; Jimenez J; Mondesir J; Lee B; Giglio P; Chandrashekar A; Abbink P; Colantonio A; Gittens C; Baker C; Wagner W; Lewis MG; Li W; Sekaly RP; Lifson JD; Burton DR; Barouch DH
    Science; 2016 Sep; 353(6303):1045-1049. PubMed ID: 27540005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques.
    Ziani W; Bauer A; Lu H; Wang X; Wu X; Bar KJ; Li H; Liu D; Shaw GM; Veazey RS; Xu H
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
    Pegu A; Xu L; DeMouth ME; Fabozzi G; March K; Almasri CG; Cully MD; Wang K; Yang ES; Dias J; Fennessey CM; Hataye J; Wei RR; Rao E; Casazza JP; Promsote W; Asokan M; McKee K; Schmidt SD; Chen X; Liu C; Shi W; Geng H; Foulds KE; Kao SF; Noe A; Li H; Shaw GM; Zhou T; Petrovas C; Todd JP; Keele BF; Lifson JD; Doria-Rose NA; Koup RA; Yang ZY; Nabel GJ; Mascola JR
    Cell Rep; 2022 Jan; 38(1):110199. PubMed ID: 34986348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques.
    Walker-Sperling VEK; Mercado NB; Chandrashekar A; Borducchi EN; Liu J; Nkolola JP; Lewis M; Murry JP; Yang Y; Geleziunas R; Robb ML; Michael NL; Pau MG; Wegmann F; Schuitemaker H; Fray EJ; Kumar MR; Siliciano JD; Siliciano RF; Barouch DH
    Nat Commun; 2022 Jun; 13(1):3463. PubMed ID: 35710819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection.
    Parsons MS; Lloyd SB; Lee WS; Kristensen AB; Amarasena T; Center RJ; Keele BF; Lifson JD; LaBranche CC; Montefiori D; Wines BD; Hogarth PM; Swiderek KM; Venturi V; Davenport MP; Kent SJ
    Sci Transl Med; 2017 Aug; 9(402):. PubMed ID: 28794282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
    Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.